Sept 2015 Drugs & Dealers Magazine Released

Biotech and Money are pleased to announce the release of the latest Drugs & Dealers Magazine. The September issue is the fourth of 6 bi-monthly publications in 2015 aimed at providing insight, foresight and hindsight to life science executives involved in funding, investment, partnering and deal making.

DOWNLOAD the PDF Magazine here

Here’s what you can expect to read from the digitally interactive September issue:

  • Attracting investment from a leading EIS fund: We talk to CEO David Venables off the back of Synpromics securing £2.1m EIS funds and uncover what this funding means for the further development of Synpromics’ proprietary synthetic promoter technology.
  • Fundraising from one of the UK’s leading investors: Newly appointed Chairman and CEO, Chris Yates discusses the potential of Abingdon Diagnostics as it stakes a claim in the $9bn global diagnostics business. With £3m investment from Imperial Innovations we ask what the immediate term holds.
  • Europe’s largest private life science investment: Fresh from their record breaking £205m private finance raising, we talk toImmunocore CEO Dr Eliot Forster and find out what it’s going to take to build one of the UK’s leading biotech businesses.
  • Transformational deal making - Oxford Biomedica: Given the recent announcement of Oxford Biomedica securing £50m loan funding to expand its lab and manufacturing facilities and service it’s transformational deal with Novartis, we find time with CEO John Dawson.
  • OSI and Oxford Nanopore Technologies: Short narratives on two of Oxford’s most impressive funding and finance raisings from the last few months. Talking through OSI’s £300m and Oxford Nanopore Technologies £70m fundraising respectively.
  • Francois Martelet, CEO and his aims for Netscientific: 3 months into his tenure as CEO of NetScientific, the vastly experienced industry executive shares his strategy and goals for the transatlantic biomedical and healthcare investment group, and what is it that makes the company’s approach unique.
  • Life is a big deal in New York City: In this spotlight case, we look at New York City as it embarks on raising it’s life science status. We assess it’s strengths, weaknesses and opportunities and ask what will it take to equal the likes of MA and CA.
  • Spotting baby biotech unicorns: The first of a regular piece written by the DrugBaron aka David Grainger, VenturePartner at Index Ventures. David shares his views on searching for billion-dollar investment winners.
  • Oxford AHSN’s role in developing special networks: Prof. Gary Ford CBE, talks through what OAHSN is doing to break down traditional organisational boundaries and building stronger relationships between industry, universities and the NHS.
  • £25m series C investment in the battle against cancer: Dr John Beadle, CEO of PsiOxus Therapeutics outlines what the investment will achieve for their pipeline of oncolytic programmes plus what’s proved so attractive to his high profile investors.
  • The critical friend - appointing NEDs: Non-executive directors are usual on the boards of most biotech companies. In some cases their appointment may be a condition of the investors but what is it they bring and what should you be looking for in a NED?
  • June Community polls: Here we share the results of the monthly Biotech and Money Community poll that has taken place during June. Look out for future polls.

Plus regular pieces ‘In Brief’ – on recent announcements in the UK funding and investment landscape and ‘Save the date’ - outlining up and coming key UK awards and grant competition deadlines.

DOWNLOAD the PDF Magazine her

Tags :

Leave a comment